James G. Christensen

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

This study shows that KRAS inhibition in lung adenocarcinoma leads to an AT1-like cell state that drives resistance, and targeting these cells improves treatment response.